Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin

Anticancer Research

Volumn 36, Issue 3, 2016, Pages 1313-1318

  Jiang, Lixin ^a   Li, Peng ^a   Gong, Zhaohua ^a   Hu, Baohong ^a   Ma, Jing ^a   Wang, Jiahui ^a   Chu, Hongjin ^a   Zhang, Liangming ^a   Sun, Ping ^a   Chen, Jian ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Ascites; Bevacizumab; Cisplatin; Intrapleural and intraperitoneal chemotherapy; Malignant pleural effusion

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CISPLATIN; ANTINEOPLASTIC AGENT;

ABDOMINAL DISTENSION; ADULT; ARTICLE; ASCITES; B SCAN; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; LUNG HEMORRHAGE; MALE; MALIGNANT PLEURA EFFUSION; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SOLID TUMOR; SURVIVAL RATE; THORACOCENTESIS; THROMBOSIS; TREATMENT RESPONSE; VOMITING; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; BEVACIZUMAB; CISPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84979590540     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hou W and Sanyal AJ: Ascites: diagnosis and management. Med Clinics N Am 93: 801-817, 2009.
2. Pourgholami MH, Yan CZ, Lu Y, Wang L and Morris DL: lbendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumorbearing nude mice. Clin Cancer Res 12: 1928-1935, 2006.
3. Rahman NM, Davies HE, Salzberg M, Truog P, Midgely R, Kerr D, Clelland C, Hedley EL, Lee YC and Davies RJ: Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. Lancet Oncol 9: 946-952, 2008.
4. Miyanaga A and Gemma A: Pleuritis carcinomatosa. Gan to kagaku ryoho Cancer & Chemotherapy 38: 524-527, 2011.
5. Saada E, Follana P, Peyrade F, Mari V and Francois E: Pathogenesis and management of refractory malignant ascites. Bull Cancer 98: 679-687, 2011.
6. Sahn SA: Management of malignant pleural effusions. Monaldi Arch for Chest Dis 56: 394-399, 2001.
7. Cattn S, Fellay B, Pradervand S, Trojan A, Ruhstaller T, Ruegg C and Furstenberger G: Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+cells and IL-10 in metastatic breast cancer patents. Oncotarget Epub, 2016.
8. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
9. Pichelmayer O, Zielinski C and Raderer M: Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med 353: 740-741, 2005.
10. Cohen MH, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718, 2007.
11. Ribeiro SC, Vargas FS, Antonangelo L, Marchi E, Genofre EH, Acencio MM and Teixeira LR: Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology 14: 1188-1193, 2009.
12. Pichelmayer O, Gruenberger B, Zielinski C and Raderer M: Bevacizumab is active in malignant effusion. Ann Oncol 17: 1853. 2006.
13. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, CArey MS, Beale P, Qian W, Swart AM, Oza A and Perren T: Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality of life outcomes from the international collaboration on ovarian neoplasms (ICON7) phase III randomised trail. Lancet Oncol 14: 236-243, 2013.
14. Zhao H, Li X, Chen D, Cai J, Fu Y, Kang H, Gao J Gao K and Du N: Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ovarian epithelial cancer: results of a phase III clinical trail. Med Oncol 32: 292, 2015.
15. Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y and Kang H: Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancermediated malignant pleural effusion. Oncol Rep 29: 2332-2340, 2013.
16. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14: 1242-1251, 2009.
17. Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J and Du N: The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion. Indian J Cancer 51: e82-85, 2014.
18. Trotti A, Byhardt R, Stetz RN, Gewede C, Corn B, Fu K, Gunderson L, McCormick B, Morris M, Rich T, Shipley W and Curran W: Common toxicity criteria: version 2. 0 an improved reference for grading the acute effects of cancer treatment:impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(1): 13-47, 2000.
19. Franklin HR, Simonetti GP, Dubbelman AC, ten Bokkel WW, Taal BG, Wigbout G, Mandjes IA, Dalesio OB and Aaronson NK: Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5(2): 113-117, 1994.
20. Yan S and Shi YK: Manual of Medical Oncology (5th edition). Prople's Medical Publishing House. 2007.
21. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW and McVie JG: Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49: 3380-3384, 1989.
22. Walker-Renard PB, Vaughan LM and Sahn SA: Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 120: 56-64, 1994.
23. Martin HC, Gootenberg J, Keegan P and Pazdur R: FDA drug approval summary: bevacizumab plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718, 2007.
24. Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, Engelmann L, Schauer J, Emmrich F and Hoheisel G: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 25: 600-604, 2005.
25. Hama M, Komatsu Y and Hachiya T: A case of lung cancer showing marked reduction of pleural effusion by bevacizumab in combination with carboplatin and paclitaxel. Gan to kagaku ryoho Cancer & Chemotherapy 38: 1877-1879, 2011.
26. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH and Rose GS: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111: 530-532, 2008.
27. Numnum TM, Rocconi RP, Whitworth J and Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102: 425-428, 2006.
28. el-Shami K, Griffiths E and Streiff M: Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist 12: 518-523, 2007.